Reviewed
Reviewed on 2026-09-19 against the evidence rules: every claim carries a grade, every claim and every safety flag carries a source, and every citation was re-resolved against the record it names. The read was delegated by the owner on 2026-09-18 and signed by the Lead on his behalf (D-295) — it is a delegated review, not the owner's own reading of the page. Every claim on it carries an evidence grade and a named weakest link. It is educational and is not medical advice.
Last reviewed
Three high-quality trials, six to forty months, and no cognitive benefit in well-nourished older adults. This is the clearest published null in the section, and the largest safety signal.
Safety
Adverse effects
Across seven cardiovascular-outcome trials and 81,210 patients, marine omega-3 supplements were associated with atrial fibrillation at a hazard ratio of 1.25 (95% confidence interval 1.07 to 1.46), and the association rose with dose: 1.49 in trials above 1 g a day against 1.12 at or below. This is the largest sample in this section, and it is a harm signal, not a benefit.
Adverse effects
Mild gastrointestinal upset was the main reported side effect in the Cochrane trials, in fewer than 15% of participants and balanced between the supplement and placebo groups.
No data in your group
The cognitive trials are in over-60s. Nobody has run a long trial of omega-3 supplements against cognition in healthy adults in their twenties and thirties, so the honest answer for that group is that it has not been tested rather than that it does not work.
Who should not
Anyone with an existing arrhythmia, or on an anticoagulant, should raise a fish-oil supplement with a clinician rather than start one on the strength of a general recommendation.
What the evidence says, and how strong it is
A grade belongs to one claim, in one population, for one preparation — never to a compound, a food or a page. Open a grade to see the four links between the evidence and the thing you would actually do, and which of them is doing the least work.
Pooling three trials judged of high methodological quality, with cognitive data on 3,536 participants at final follow-up, omega-3 supplementation made no difference to the MMSE — a mean difference of −0.07 (95% confidence interval −0.25 to 0.10) — and no difference to word learning, digit span or verbal fluency either.
Evidence grade A: Evidence supportsIn whom: Cognitively healthy adults aged 60 and over
What form: EPA/DHA capsules or enriched margarine, 6 to 40 months
Measured as: Global cognition on the MMSE, and word learning, digit span and verbal fluency
Evidence does not support
Why this grade
- Weakest link
- Population — the people studied are not the people reading. Three high-quality trials in cognitively healthy over-60s: the null is as solid as this section gets, and it is a null about over-60s.
- What was actually studied
- Cognitively healthy people aged 60 and over, 6 to 40 months of supplementation (n = 3536, with cognitive data at final follow-up, of 4,080 randomised; 3,221 contributed to the MMSE comparison)
- Detail worth knowing
- MMSE at final follow-up: mean difference −0.07 (95% CI −0.25 to 0.10) across two studies and 3,221 participants. Word learning, digit span and verbal fluency showed no benefit either. All three included studies were judged of high methodological quality.
Across 24 randomised trials, omega-3 supplementation did not improve any cognitive performance measure in the whole sample or in either subgroup. The review's own conclusion is that claims of cognitive benefit should be narrowed.
Evidence grade A: Evidence supportsIn whom: Typically developing adults and children, and people with ADHD
What form: Omega-3 supplementation across 24 randomised trials
Measured as: Any measure of cognitive performance
Evidence does not support
Why this grade
- Weakest link
- Population — the people studied are not the people reading. The 24 trials pool typically developing adults and children with people who have ADHD, so the null covers a wide group rather than describing one.
- What was actually studied
- Adults and school-aged children, typically developing and with ADHD, 24 trials
- Detail worth knowing
- No improvement on any cognitive performance measure in the whole sample or either subgroup. Short-term memory improved in those with low omega-3 status. The authors' own conclusion: "claims of cognitive benefit should be narrowed."
In the subgroup with low omega-3 status to begin with, short-term memory improved. This is the one positive result in the pooled literature, it comes from a subgroup rather than a trial designed to find it, and it is about correcting a shortfall rather than adding to an adequate intake.
Evidence grade C: Early research suggestsIn whom: Adults with low omega-3 status
What form: Omega-3 supplementation, doses and durations as in the pooled trials
Measured as: Short-term memory
Why this grade
- Weakest link
- Population — the people studied are not the people reading. It is a subgroup of people already low in omega-3, found inside a meta-analysis whose main result was null, rather than a group a trial was designed around.
- What was actually studied
- Adults and school-aged children, typically developing and with ADHD, 24 trials
- Detail worth knowing
- No improvement on any cognitive performance measure in the whole sample or either subgroup. Short-term memory improved in those with low omega-3 status. The authors' own conclusion: "claims of cognitive benefit should be narrowed."
Everything above, and where it comes from
- Sydenham E, Dangour AD, Lim WS (2012). Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database of Systematic Reviews 2012(6):CD005379.pub3
- Cooper RE, Tye C, Kuntsi J, Vassos E, Asherson P (2015). Omega-3 polyunsaturated fatty acid supplementation and cognition: A systematic review and meta-analysis. Journal of Psychopharmacology 29(7):753–763
- Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM (2021). Effect of Long-Term Marine ω-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation 144(25):1981–1990
The one thing worth doing
Oily fish twice a week puts you in the group these trials found nothing to improve. That is the good outcome, and it belongs to Brain Diet rather than to a capsule.
Regulatory note — this note has not yet been reviewed by a lawyer. In the United States, supplements are sold under DSHEA: a structure/function claim is not reviewed by the FDA before it appears, and the label must carry the words "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." In the EU and the UK, only health claims on the authorised register may be used in advertising, and a food or supplement advertisement may not say a product prevents, treats or cures a disease. Whether an evidence page that carried a purchase link would itself count as advertising under those rules is an open question that counsel, not this page, will answer; there are no purchase links here. Nothing on this page is medical advice.